Peter Wilmshurst replies to Jonathan Gornall
BMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c1195 (Published 02 March 2010) Cite this as: BMJ 2010;340:c1195
- Peter Wilmshurst, consultant cardiologist1
- 1Royal Shrewsbury Hospital, Shrewsbury SY3 8XQ
- peter.wilmshurst{at}tiscali.co.uk
Jonathan Gornall has tried to clarify the issues in the MIST trial and NMT Medical’s libel action against me, but he has made some errors.1
His statement that “the trial ran from January to July 2005” is taken from NMT’s particulars of claim and is wrong. NMT now concedes in the company’s reply to my defence that the clinical phase was from “November 2004 to early 2006.”
Gornall states that my finding of a high residual shunt rate “seemed to contradict clinical experience with the device, including a 2006 study that had reviewed outcomes in 42 cases in which atrial septal defects had been repaired with STARFlex and found complete closure in 39 (93%) ….”2 The letter before claim from NMT’s lawyers also makes that argument, but …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.